Stent R&D Operations established in NJ

Stentys has established U.S. operations in Princeton, N.J., where the company will focus its R&D efforts. The Princeton operation will be the cornerstone of the company’s efforts when seeking FDA clearance to market its self-expanding and disconnectable stent platform.

“Establishing U.S. operations is a major milestone for Stentys’ future commercial launch,” says CEO and co-founder, Gonzague Issenmann. “This is a very exciting time as we are also establishing a radically innovative and improved treatment for acute coronary syndrome (ACS).”

ACS procedures represent half of the $5 billion coronary stenting market. But today’s treatment with balloon-expandable stents is plagued by a high incidence of malapposition, a major predictor of stent thrombosis, and that caps the market at a lower value.

“Stentys’ platform solves malapposition thanks to its self-expanding feature that ensures optimal apposition in the critical hours and days after the procedure. The stent is constantly applied to the vessel surface during thrombus and vessel spasm relief, as demonstrated in the successful initial clinical experience,” Issenmann explains.

About Stentys
Based in Princeton, N.J., and Paris, Stentys intends to make treatment of complex blocked coronary arteries as simple and effective as a conventional stenting procedure. The Company announced in March 2009 that it has started the APPOSITION I trial to investigate the use of the Stentys stent in STEMI patients. Stentys was co-founded by Gonzague Issenmann and Jacques Séguin, M.D., Ph.D., founder of CoreValve, which was acquired this year by Medtronic for $850 million.